Pharma Wholesale and Distribution Market: World Outlook 2013-2023
Discover trends and revenue potential in distributing and wholesaling of medicines
Where's the drug wholesaling and distribution market heading? Visiongain's updated report predicts revenues there from 2013 to 2023. It also explains trends in business and technology, prospects, and opportunities to help your work.
In that study you gain sales forecasts at overall world market, submarket, company, and national level. Find what's happening. Also discover what has most growth potential.
Read on to explore the drug distribution industry and see what its future market could be worth.
Forecasts and other information to benefit your knowledge
Is finding data a challenge? Avoid falling behind for supply of medicines. You can now stay ahead in information, benefiting your research, analyses, and decisions. Also save time.
Besides revenue forecasting, our new work shows historical data, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and developments. You also gain 68 tables, 95 charts, and three research interviews.
There you investigate the future of the supply chain for human medicines. You find what's happening and see where the money lies. Finding data you need has just got easier.
Anyhow, the following sections show what you get in our investigation and analysis.
See prospects for the world market and submarkets
Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts for three submarkets:
Also our study discusses what stimulates and restrains business for distributing drugs. That analysis helps you identify potential and find ways for your business to grow.
You also see geographical revenue predictions.
What sales potential for leading countries?
Developments worldwide expand the pharma W&D market, especially rising demand for medicines in emerging countries. China, India, Russia, and Brazil underpin revenue growth.
In developed and developing countries, opportunities for drug wholesalers and other medical suppliers will occur from 2013. Pharmacies also stand to benefit. See how.
Our report shows you individual revenue forecasts to 2023 for 11 national markets:
That analysis shows highest revenue growth to 2023 will occur in developing countries. Developed markets will expand too. You investigate, also finding the potential of companies.
Find revenue forecasts and other information for leading firms
How will leading companies perform to 2023 at world level? Our work shows you individual revenue forecasts for 11 top wholesalers and distributors, including these:
That way you assess the future, hearing about progress and finding its significance. Our study explains, exploring many issues.
What affects the supply of pharmaceuticals through distribution networks?
Our report discusses issues and events affecting that industry and market from 2013, including these:
See, then, what the future holds.
What's the 2017 market value?
Our study predicts the world market for drug wholesaling and distribution will reach $966bn in 2017, and expand further to 2023. See how high turnover can go, and find what influences revenues and profits.
Also, some medical wholesalers and distributers are expanding into retail pharmacy, and even into drug production. W&D evolves - you see how and assess its future.
Discover now revenues and opportunities for the W&D industry - established and rising companies. That market holds potential from 2013 for investment, development, and sales growth. Our new report shows you the possibilities.
Nine ways Pharma Wholesale and Distribution Market: World Outlook 2013-2023 helps
To sum up, our analysis gives you the following knowledge:
That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions, also saving time and getting you recognition for insight.
Our analysis costs only a tiny fraction of potential profits from your understanding and harnessing the pharma W&D market. See its growth potential and find what you can gain.
Ordering now lets you discover predictions and opportunities for drug supply
Our new study is for everyone analysing the industry and market for supplying medicines. There you find data, trends, opportunities, and growth predictions. Avoid missing out - please order our report now.
Where's the drug wholesaling and distribution market heading? Visiongain's updated report predicts revenues there from 2013 to 2023. It also explains trends in business and technology, prospects, and opportunities to help your work.
In that study you gain sales forecasts at overall world market, submarket, company, and national level. Find what's happening. Also discover what has most growth potential.
Read on to explore the drug distribution industry and see what its future market could be worth.
Forecasts and other information to benefit your knowledge
Is finding data a challenge? Avoid falling behind for supply of medicines. You can now stay ahead in information, benefiting your research, analyses, and decisions. Also save time.
Besides revenue forecasting, our new work shows historical data, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and developments. You also gain 68 tables, 95 charts, and three research interviews.
There you investigate the future of the supply chain for human medicines. You find what's happening and see where the money lies. Finding data you need has just got easier.
Anyhow, the following sections show what you get in our investigation and analysis.
See prospects for the world market and submarkets
Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts for three submarkets:
- Original branded drugs
- Generic drugs
- Other products.
Also our study discusses what stimulates and restrains business for distributing drugs. That analysis helps you identify potential and find ways for your business to grow.
You also see geographical revenue predictions.
What sales potential for leading countries?
Developments worldwide expand the pharma W&D market, especially rising demand for medicines in emerging countries. China, India, Russia, and Brazil underpin revenue growth.
In developed and developing countries, opportunities for drug wholesalers and other medical suppliers will occur from 2013. Pharmacies also stand to benefit. See how.
Our report shows you individual revenue forecasts to 2023 for 11 national markets:
- US
- Japan
- Germany, France, UK, Italy, and Spain (EU5)
- Brazil, Russia, India, and China (BRIC).
That analysis shows highest revenue growth to 2023 will occur in developing countries. Developed markets will expand too. You investigate, also finding the potential of companies.
Find revenue forecasts and other information for leading firms
How will leading companies perform to 2023 at world level? Our work shows you individual revenue forecasts for 11 top wholesalers and distributors, including these:
- McKesson
- Cardinal Health
- AmerisourceBergen
- Alliance Boots
- PHOENIX
- Medipal
- Sinopharm
- Suzuken.
That way you assess the future, hearing about progress and finding its significance. Our study explains, exploring many issues.
What affects the supply of pharmaceuticals through distribution networks?
Our report discusses issues and events affecting that industry and market from 2013, including these:
- Roles of pharmaceutical wholesalers
- Revenues, costs, and profits
- Use of new technologies
- Direct-to-pharmacy (DTP) activities
- Pharmacy benefit managers
- Forward buying and fee-for-service
- Discounts, clawbacks, and parallel trade.
- Chain pharmacies and vertical integration
- State-funded healthcare and reimbursement
- Pre-wholesaling and pre-financing
- Rise of specialty medicines, including biologics, and generic drugs (generics)
- Actions against pharmaceutical counterfeiting
- Budget cuts in healthcare
- Changes to regulations
- Globalisation and consolidation of the industry.
See, then, what the future holds.
What's the 2017 market value?
Our study predicts the world market for drug wholesaling and distribution will reach $966bn in 2017, and expand further to 2023. See how high turnover can go, and find what influences revenues and profits.
Also, some medical wholesalers and distributers are expanding into retail pharmacy, and even into drug production. W&D evolves - you see how and assess its future.
Discover now revenues and opportunities for the W&D industry - established and rising companies. That market holds potential from 2013 for investment, development, and sales growth. Our new report shows you the possibilities.
Nine ways Pharma Wholesale and Distribution Market: World Outlook 2013-2023 helps
To sum up, our analysis gives you the following knowledge:
- Revenue to 2023 for the world pharma W&D market - discover that industry's sales potential
- Revenues to 2023 for 3 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and revenues
- Revenues to 2023 for 11 leading companies - find sales forecasts for top players, seeing how those participants can compete and succeed
- Forecasts to 2023 for 11 leading national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth
- Activities of leading companies - analyse participants' results, actions, capabilities, and outlooks
- Discussions of progress and market expansion - investigate developments, exploring possibilities for technological and commercial advances
- Interviews with authorities - discover debates and opinions to help you stay ahead
- Competition and opportunities - see what affects the W&D industry, learning what shapes its future, esp. prospects for sustaining and developing business
- Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages.
That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions, also saving time and getting you recognition for insight.
Our analysis costs only a tiny fraction of potential profits from your understanding and harnessing the pharma W&D market. See its growth potential and find what you can gain.
Ordering now lets you discover predictions and opportunities for drug supply
Our new study is for everyone analysing the industry and market for supplying medicines. There you find data, trends, opportunities, and growth predictions. Avoid missing out - please order our report now.
1. EXECUTIVE SUMMARY
1.1 Overview of the Study
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
2. INTRODUCTION TO PHARMA WHOLESALE AND DISTRIBUTION
2.1 The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry
2.1.1 Full-Line Wholesalers (FLWs)
2.1.2 Short-Line Wholesalers (SLWs)
2.2 The Chain of Distribution: Wholesalers vs. Logistics Service Providers
2.2.1 Secondary Wholesalers
2.2.2 Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent
2.2.3 Major Wholesalers: Distribute a Large Amount of Products to Generate High Profit
2.2.4 Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain
2.2.5 Pharmacy Benefit Managers
2.3 Generating Revenue and Profit
2.3.1 Forward Buying to Avoid Price Increases
2.3.2 Fee-for-Service: A Clearer Pricing Structure
2.3.2.1 Inventory Management Agreements
2.3.3 Discounts: Incentives for Prompt Payment or Bulk Purchases
2.3.4 Reimbursement and Wholesalers
2.3.5 Clawback: The Recovery of Reimbursement Costs by Governments
2.3.6 Parallel Trade: Different Attitudes in Europe and the US
3. THE WORLD PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET, 2013-2023
3.1 The World Pharmaceutical Wholesale and Distribution Market in 2012: Restricted by Government Price Reductions and Generic Substitution
3.2 Pharmaceutical Wholesale and Distribution: World Market Forecast, 2013-2023
3.3 Branded and Generic Drugs: Revenue vs. Profit
3.3.1 Branded and Generic Drugs: Revenue Generation, 2012
3.3.2 Branded, Generic Drugs and Others: Revenue Forecasts, 2013-2023
3.3.3 Branded Drugs: Revenue Forecast, 2013-2023
3.3.4 Generic Drugs: Revenue Forecast, 2013-2023
4. PHARMACEUTICAL WHOLESALE AND DISTRIBUTION INDUSTRY: LEADING NATIONAL MARKETS, 2013-2023
4.1 The Leading National Markets: The US Dominates in 2012
4.2 The Future of the Leading National Markets: Will the US Continue to Dominate the Market?
4.3 The US Pharma Wholesale and Distribution Market
4.3.1 The Budget Control Act and its Effect on the US W&D Industry
4.3.2 Legislation to Prevent Counterfeit Drugs Can Differ Between States
4.3.3 An Increase in Fee-For-Service Activity
4.3.4 Pharma W&D in the US: Market Forecast, 2013-2023
4.4 The Leading European (EU5) Pharma Wholesale and Distribution Markets
4.4.1 Differences Between the US and Europe
4.4.2 State-Funded Healthcare and Reimbursement
4.4.3 EU5: Market Forecast, 2013-2023
4.4.4 Germany
4.4.4.1 Healthcare Reform
4.4.4.2 Market Forecast, 2013-2023
4.4.5 France
4.4.5.1 France: Market Forecast, 2013-2023
4.4.6 Italy
4.4.6.1 Market Forecast, 2013-2023
4.4.7 Spain
4.4.7.1 Market Forecast, 2013-2023
4.4.8 The UK
4.4.8.1 Price Cuts
4.4.8.2 Market Forecast, 2013-2023
4.5 The Japanese Pharma Wholesale and Distribution Market
4.5.1 Drug Pricing and Performance Fees
4.5.2 Japan: Market Forecast, 2013-2023
4.6 The Chinese Pharma Wholesale and Distribution Market
4.6.1 Leading Companies in the Chinese Market
4.6.2 China: Market Forecast, 2013-2023
4.7 The Brazilian Pharma Wholesale and Distribution Market
4.7.1 Drug Pricing Controls in Brazil
4.7.2 Leading Companies
4.7.3 Brazil: Market Forecast, 2013-2023
4.8 The Indian Pharma Wholesale and Distribution Market
4.8.1 India: Market Forecast, 2013-2023
4.9 The Russian Pharma Wholesale and Distribution Market
4.9.1 Drug Pricing Controls in Russia
4.9.2 Market Trends
4.9.3 Russia: Market Forecast, 2013-2023
4.10 Concluding Comments
5. LEADING PHARMA WHOLESALERS AND DISTRIBUTORS: CURRENT AND FUTURE PERFORMANCE
5.1 The Leading Companies in 2012: 11 Companies Account for 70% of the Market
5.2 Revenue vs. Profit
5.3 Leading Companies: Grouped Forecasts, 2013-2023
5.4 McKesson: The Oldest and Largest Company in the US
5.4.1 Recent Performance: Strong Growth in 2012
5.4.2 Future Strategies: A Future in Speciality Pharmaceuticals
5.4.3 Revenue Forecast, 2013-2023
5.5 Cardinal Health: The World's Second Largest Pharma Wholesaler
5.5.1 Recent Performance: Acquisitions are Driving Growth
5.5.2 Future Strategies
5.5.3 Revenue Forecast, 2013-2023
5.6 AmerisourceBergen: Responsible for 20% of Pharmaceutical Distribution in the US
5.6.1 Recent Performance: Working to Streamline Operations
5.6.2 New Contracts With Express Scripts and Walgreen's
5.6.3 Future Strategies: What's on the Horizon?
5.6.4 Revenue Forecast, 2013-2023
5.7 Alliance Boots: The Largest European Wholesaler
5.7.1 Recent Performance: Strong Growth Seen in 2012
5.7.2 Future Strategies: Expansion into the Emerging Markets
5.7.3 Revenue Forecast, 2013-2023
5.8 Medipal: Japan's Leading Pharmaceutical Wholesaler
5.8.1 Recent Performance: Revenue has Been Steadily Increasing
5.8.2 Future Strategies: Seeking to Reduce Distribution Costs
5.8.3 Revenue Forecast, 2013-2023
5.9 Celesio: Operations in 13 Countries
5.9.1 Recent Performance: Improvement of Profit Margins as a Result of Business Realignment
5.9.2 Future Strategies: Focusing on Regional Expansion
5.9.3 Revenue Forecast, 2013-2023
5.10 Alfresa Holdings: Involved in Manufacturing as Well as Wholesale
5.10.1 Recent Performance: Profit Generation Has Remained Steady
5.10.2 Future Strategies: Targeting Nationwide Coverage
5.10.3 Revenue Forecast, 2013-2023
5.11 The PHOENIX Group: One of the Top 3 Wholesalers in Europe
5.11.1 Recent Performance: A Reduction in Revenue, But an Increase in Profit
5.11.2 Future Strategies: Growth Through Acquisitions
5.11.3 Revenue Forecast, 2013-2023
5.12 Sinopharm: The Leading Wholesaler In China
5.12.1 Recent Performance: Rapid Growth in Revenue Seen
5.12.2 Future Strategies: Increasing Operations Through Business Acquisitions
5.12.3 Revenue Forecast, 2013-2023
5.13 Suzuken: The First Nationwide Wholesaler of Japan
5.13.1 Recent Performance
5.13.2 Future Strategies: Improving Profit Margins in the Face of Increased Competition
5.13.3 Revenue Forecast, 2013-2023
5.14 Shanghai Pharma: China's Second Largest Wholesaler
5.14.1 Recent Performance: Expanding Operations and Rapidly Increasing Revenue
5.14.2 Future Strategies: External Expansion As Well As Internal Growth
5.14.3 Revenue Forecast, 2013-2023
6. QUALITATIVE ANALYSIS OF THE PHARMA WHOLESALE AND DISTRIBUTION MARKET
6.1 Strengths and Weaknesses of the Pharma Wholesale and Distribution Market, 2013
6.1.1 The Insatiable Demand for Drugs: A Recession-Proof Industry?
6.1.2 Wholesalers Do More than Deliver Drugs
6.1.2.1 Pre-Wholesaling: More Prevalent in Europe
6.1.2.2 Through Pre-Financing, Full-Line Wholesalers Finance the Entire Medicines Market
6.1.3 Large Companies Dominate the Market
6.1.4 Despite High Revenues, Profit Margins Are Low
6.1.5 Government-Induced Drug Price Pressures Restrict Profits
6.1.6 The Problem of Counterfeit Drugs
6.1.6.1 The Adoption of Anti-Counterfeiting Measures
6.2 The Opportunities and Threats Facing the Pharma Wholesale and Distribution Market, 2013-2023
6.2.1 The Demand for Pharmaceuticals is Increasing
6.2.2 The Increasing Use of Speciality Drugs Will Drive Growth
6.2.3 The Increasing Use of Generic Drugs Will Restrict Revenue, But Drive Profit Generation
6.2.4 The Promotion of Drug Therapy in the US
6.2.5 Globalisation: The Major National Markets are Dominated by Few Companies
6.2.6 Increased Adoption of the DTP Distribution Model
6.2.6.1 DTP in Europe: The First Place the Scheme Has Taken Hold
6.2.6.2 DTP in the UK Since 1991
6.2.6.3 DTP in Poland: The Second European Country to Adopt the DTP Model
6.2.6.4 Further Expansion of the DTP Model
6.2.7 The Threat of Healthcare Budget Cuts
6.2.7.1 Healthcare Budget Cuts in Germany
6.2.7.2 Healthcare Budget Cuts in France
6.2.7.3 Healthcare Budget Cuts in Italy
6.2.7.4 Healthcare Budget Cuts in Spain
6.2.7.5 Healthcare Budget Cuts in the UK
6.2.8 Do Large Chain Pharmacies Pose a Threat?
6.2.8.1 Case Study: Walmart and the $4 Prescription Scheme
6.2.8.2 Vertical Integration of Wholesalers: A Response to the Threat of Chain Pharmacies
6.2.9 Does the Diversion and Re-importation of Medicines Pose a Threat to the Industry?
6.2.10 The Threat of Industry Consolidation
6.3 Social, Technological, Economical and Political Factors Influencing the Market, 2013-2023 (STEP Analysis)
6.3.1 Political Factor: The Impact of Recent Regulatory Changes in the EU
6.3.2 Political Factor: Combating Counterfeit Medicines
6.3.2.1 The US and E-Pedigree: Becoming Law in California
6.3.2.2 European Pedigree Legislation
6.3.2.3 Anti-Counterfeiting Strategies in Other Markets: The Chinese Government Is Attempting to Address the Challenge
6.3.2.4 Serialisation for Wholesalers: Opportunity or a Challenge?
7. RESEARCH INTERVIEWS
7.1 Interview with Dr Evelyn Walter, Co-Founder and Director of the Institute for Pharmaeconomic Research (IPF), Vienna
7.1.1 On Direct-to-Pharmacy Distribution
7.1.2 On the Effect of Drug Pricing Pressures on the Supply of Pharmaceuticals
7.1.3 On the Role of Pharmaceutical Wholesalers and Distributors in European Healthcare Systems
7.1.4 On the Impact of Counterfeit Drugs
7.1.5 On the Efficacy of the Pharmaceutical W&D Industry
7.2 Interview with Monika Derecque-Pois, Director General, European Association of Pharmaceutical Full-line Wholesalers (GIRP)
7.2.1 On Key Unmet Needs in the Industry
7.2.2 On the Impact of Recent Regulatory Changes
7.2.3 On the Value-Added Services Offered by Pharmaceutical Wholesalers
7.2.4 On the Use of Novel Technologies
7.3 Interview with Geoff Mellor and Martin Sawer, British Association of Pharmaceutical Wholesalers (BAPW)
7.3.1 On the Impact of Recent Regulatory Changes
7.3.2 On the Impact of New Technologies
7.3.3 Fast-Growing Sectors?
8. CONCLUSIONS FROM THE STUDY
8.1 The Future of the Pharma Wholesale and Distribution Market
8.2 The Leading National Pharma Wholesale and Distribution Markets
8.3 Leading Companies in the Industry
8.4 Trends in the Industry and Market
8.4.1 Generics Will Threaten Revenues
8.4.2 Manufacturers Will Deliver More Drugs Directly
8.4.3 There Will Be Greater Demand for Specialty Medicines
8.4.4 Consolidation Will Drive Growth
8.4.5 Anti-Counterfeiting Demands Will Add to Wholesalers' Costs
1.1 Overview of the Study
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
2. INTRODUCTION TO PHARMA WHOLESALE AND DISTRIBUTION
2.1 The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry
2.1.1 Full-Line Wholesalers (FLWs)
2.1.2 Short-Line Wholesalers (SLWs)
2.2 The Chain of Distribution: Wholesalers vs. Logistics Service Providers
2.2.1 Secondary Wholesalers
2.2.2 Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent
2.2.3 Major Wholesalers: Distribute a Large Amount of Products to Generate High Profit
2.2.4 Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain
2.2.5 Pharmacy Benefit Managers
2.3 Generating Revenue and Profit
2.3.1 Forward Buying to Avoid Price Increases
2.3.2 Fee-for-Service: A Clearer Pricing Structure
2.3.2.1 Inventory Management Agreements
2.3.3 Discounts: Incentives for Prompt Payment or Bulk Purchases
2.3.4 Reimbursement and Wholesalers
2.3.5 Clawback: The Recovery of Reimbursement Costs by Governments
2.3.6 Parallel Trade: Different Attitudes in Europe and the US
3. THE WORLD PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET, 2013-2023
3.1 The World Pharmaceutical Wholesale and Distribution Market in 2012: Restricted by Government Price Reductions and Generic Substitution
3.2 Pharmaceutical Wholesale and Distribution: World Market Forecast, 2013-2023
3.3 Branded and Generic Drugs: Revenue vs. Profit
3.3.1 Branded and Generic Drugs: Revenue Generation, 2012
3.3.2 Branded, Generic Drugs and Others: Revenue Forecasts, 2013-2023
3.3.3 Branded Drugs: Revenue Forecast, 2013-2023
3.3.4 Generic Drugs: Revenue Forecast, 2013-2023
4. PHARMACEUTICAL WHOLESALE AND DISTRIBUTION INDUSTRY: LEADING NATIONAL MARKETS, 2013-2023
4.1 The Leading National Markets: The US Dominates in 2012
4.2 The Future of the Leading National Markets: Will the US Continue to Dominate the Market?
4.3 The US Pharma Wholesale and Distribution Market
4.3.1 The Budget Control Act and its Effect on the US W&D Industry
4.3.2 Legislation to Prevent Counterfeit Drugs Can Differ Between States
4.3.3 An Increase in Fee-For-Service Activity
4.3.4 Pharma W&D in the US: Market Forecast, 2013-2023
4.4 The Leading European (EU5) Pharma Wholesale and Distribution Markets
4.4.1 Differences Between the US and Europe
4.4.2 State-Funded Healthcare and Reimbursement
4.4.3 EU5: Market Forecast, 2013-2023
4.4.4 Germany
4.4.4.1 Healthcare Reform
4.4.4.2 Market Forecast, 2013-2023
4.4.5 France
4.4.5.1 France: Market Forecast, 2013-2023
4.4.6 Italy
4.4.6.1 Market Forecast, 2013-2023
4.4.7 Spain
4.4.7.1 Market Forecast, 2013-2023
4.4.8 The UK
4.4.8.1 Price Cuts
4.4.8.2 Market Forecast, 2013-2023
4.5 The Japanese Pharma Wholesale and Distribution Market
4.5.1 Drug Pricing and Performance Fees
4.5.2 Japan: Market Forecast, 2013-2023
4.6 The Chinese Pharma Wholesale and Distribution Market
4.6.1 Leading Companies in the Chinese Market
4.6.2 China: Market Forecast, 2013-2023
4.7 The Brazilian Pharma Wholesale and Distribution Market
4.7.1 Drug Pricing Controls in Brazil
4.7.2 Leading Companies
4.7.3 Brazil: Market Forecast, 2013-2023
4.8 The Indian Pharma Wholesale and Distribution Market
4.8.1 India: Market Forecast, 2013-2023
4.9 The Russian Pharma Wholesale and Distribution Market
4.9.1 Drug Pricing Controls in Russia
4.9.2 Market Trends
4.9.3 Russia: Market Forecast, 2013-2023
4.10 Concluding Comments
5. LEADING PHARMA WHOLESALERS AND DISTRIBUTORS: CURRENT AND FUTURE PERFORMANCE
5.1 The Leading Companies in 2012: 11 Companies Account for 70% of the Market
5.2 Revenue vs. Profit
5.3 Leading Companies: Grouped Forecasts, 2013-2023
5.4 McKesson: The Oldest and Largest Company in the US
5.4.1 Recent Performance: Strong Growth in 2012
5.4.2 Future Strategies: A Future in Speciality Pharmaceuticals
5.4.3 Revenue Forecast, 2013-2023
5.5 Cardinal Health: The World's Second Largest Pharma Wholesaler
5.5.1 Recent Performance: Acquisitions are Driving Growth
5.5.2 Future Strategies
5.5.3 Revenue Forecast, 2013-2023
5.6 AmerisourceBergen: Responsible for 20% of Pharmaceutical Distribution in the US
5.6.1 Recent Performance: Working to Streamline Operations
5.6.2 New Contracts With Express Scripts and Walgreen's
5.6.3 Future Strategies: What's on the Horizon?
5.6.4 Revenue Forecast, 2013-2023
5.7 Alliance Boots: The Largest European Wholesaler
5.7.1 Recent Performance: Strong Growth Seen in 2012
5.7.2 Future Strategies: Expansion into the Emerging Markets
5.7.3 Revenue Forecast, 2013-2023
5.8 Medipal: Japan's Leading Pharmaceutical Wholesaler
5.8.1 Recent Performance: Revenue has Been Steadily Increasing
5.8.2 Future Strategies: Seeking to Reduce Distribution Costs
5.8.3 Revenue Forecast, 2013-2023
5.9 Celesio: Operations in 13 Countries
5.9.1 Recent Performance: Improvement of Profit Margins as a Result of Business Realignment
5.9.2 Future Strategies: Focusing on Regional Expansion
5.9.3 Revenue Forecast, 2013-2023
5.10 Alfresa Holdings: Involved in Manufacturing as Well as Wholesale
5.10.1 Recent Performance: Profit Generation Has Remained Steady
5.10.2 Future Strategies: Targeting Nationwide Coverage
5.10.3 Revenue Forecast, 2013-2023
5.11 The PHOENIX Group: One of the Top 3 Wholesalers in Europe
5.11.1 Recent Performance: A Reduction in Revenue, But an Increase in Profit
5.11.2 Future Strategies: Growth Through Acquisitions
5.11.3 Revenue Forecast, 2013-2023
5.12 Sinopharm: The Leading Wholesaler In China
5.12.1 Recent Performance: Rapid Growth in Revenue Seen
5.12.2 Future Strategies: Increasing Operations Through Business Acquisitions
5.12.3 Revenue Forecast, 2013-2023
5.13 Suzuken: The First Nationwide Wholesaler of Japan
5.13.1 Recent Performance
5.13.2 Future Strategies: Improving Profit Margins in the Face of Increased Competition
5.13.3 Revenue Forecast, 2013-2023
5.14 Shanghai Pharma: China's Second Largest Wholesaler
5.14.1 Recent Performance: Expanding Operations and Rapidly Increasing Revenue
5.14.2 Future Strategies: External Expansion As Well As Internal Growth
5.14.3 Revenue Forecast, 2013-2023
6. QUALITATIVE ANALYSIS OF THE PHARMA WHOLESALE AND DISTRIBUTION MARKET
6.1 Strengths and Weaknesses of the Pharma Wholesale and Distribution Market, 2013
6.1.1 The Insatiable Demand for Drugs: A Recession-Proof Industry?
6.1.2 Wholesalers Do More than Deliver Drugs
6.1.2.1 Pre-Wholesaling: More Prevalent in Europe
6.1.2.2 Through Pre-Financing, Full-Line Wholesalers Finance the Entire Medicines Market
6.1.3 Large Companies Dominate the Market
6.1.4 Despite High Revenues, Profit Margins Are Low
6.1.5 Government-Induced Drug Price Pressures Restrict Profits
6.1.6 The Problem of Counterfeit Drugs
6.1.6.1 The Adoption of Anti-Counterfeiting Measures
6.2 The Opportunities and Threats Facing the Pharma Wholesale and Distribution Market, 2013-2023
6.2.1 The Demand for Pharmaceuticals is Increasing
6.2.2 The Increasing Use of Speciality Drugs Will Drive Growth
6.2.3 The Increasing Use of Generic Drugs Will Restrict Revenue, But Drive Profit Generation
6.2.4 The Promotion of Drug Therapy in the US
6.2.5 Globalisation: The Major National Markets are Dominated by Few Companies
6.2.6 Increased Adoption of the DTP Distribution Model
6.2.6.1 DTP in Europe: The First Place the Scheme Has Taken Hold
6.2.6.2 DTP in the UK Since 1991
6.2.6.3 DTP in Poland: The Second European Country to Adopt the DTP Model
6.2.6.4 Further Expansion of the DTP Model
6.2.7 The Threat of Healthcare Budget Cuts
6.2.7.1 Healthcare Budget Cuts in Germany
6.2.7.2 Healthcare Budget Cuts in France
6.2.7.3 Healthcare Budget Cuts in Italy
6.2.7.4 Healthcare Budget Cuts in Spain
6.2.7.5 Healthcare Budget Cuts in the UK
6.2.8 Do Large Chain Pharmacies Pose a Threat?
6.2.8.1 Case Study: Walmart and the $4 Prescription Scheme
6.2.8.2 Vertical Integration of Wholesalers: A Response to the Threat of Chain Pharmacies
6.2.9 Does the Diversion and Re-importation of Medicines Pose a Threat to the Industry?
6.2.10 The Threat of Industry Consolidation
6.3 Social, Technological, Economical and Political Factors Influencing the Market, 2013-2023 (STEP Analysis)
6.3.1 Political Factor: The Impact of Recent Regulatory Changes in the EU
6.3.2 Political Factor: Combating Counterfeit Medicines
6.3.2.1 The US and E-Pedigree: Becoming Law in California
6.3.2.2 European Pedigree Legislation
6.3.2.3 Anti-Counterfeiting Strategies in Other Markets: The Chinese Government Is Attempting to Address the Challenge
6.3.2.4 Serialisation for Wholesalers: Opportunity or a Challenge?
7. RESEARCH INTERVIEWS
7.1 Interview with Dr Evelyn Walter, Co-Founder and Director of the Institute for Pharmaeconomic Research (IPF), Vienna
7.1.1 On Direct-to-Pharmacy Distribution
7.1.2 On the Effect of Drug Pricing Pressures on the Supply of Pharmaceuticals
7.1.3 On the Role of Pharmaceutical Wholesalers and Distributors in European Healthcare Systems
7.1.4 On the Impact of Counterfeit Drugs
7.1.5 On the Efficacy of the Pharmaceutical W&D Industry
7.2 Interview with Monika Derecque-Pois, Director General, European Association of Pharmaceutical Full-line Wholesalers (GIRP)
7.2.1 On Key Unmet Needs in the Industry
7.2.2 On the Impact of Recent Regulatory Changes
7.2.3 On the Value-Added Services Offered by Pharmaceutical Wholesalers
7.2.4 On the Use of Novel Technologies
7.3 Interview with Geoff Mellor and Martin Sawer, British Association of Pharmaceutical Wholesalers (BAPW)
7.3.1 On the Impact of Recent Regulatory Changes
7.3.2 On the Impact of New Technologies
7.3.3 Fast-Growing Sectors?
8. CONCLUSIONS FROM THE STUDY
8.1 The Future of the Pharma Wholesale and Distribution Market
8.2 The Leading National Pharma Wholesale and Distribution Markets
8.3 Leading Companies in the Industry
8.4 Trends in the Industry and Market
8.4.1 Generics Will Threaten Revenues
8.4.2 Manufacturers Will Deliver More Drugs Directly
8.4.3 There Will Be Greater Demand for Specialty Medicines
8.4.4 Consolidation Will Drive Growth
8.4.5 Anti-Counterfeiting Demands Will Add to Wholesalers' Costs
LIST OF TABLES
Table 2.1 Use of the DTP Model in the UK, 2013
Table 3.1 Pharmaceutical Wholesale and Distribution: World Market Forecast, 2012-2023
Table 3.2 Pharmaceutical W&D: Branded, Generic Drugs and Others, Revenue Forecasts, 2012-2023
Table 3.3 W&D of Branded Drugs: Revenue Forecast, 2012-2023
Table 3.4 W&D of Generic Drugs: Revenue Forecast, 2012-2023
Table 4.1 The Leading National Markets: Revenues and Market Shares, 2012
Table 4.2 The Leading National Markets: Revenue Forecasts, 2012-2023
Table 4.3 Breakdown of the US Market: The 3 Leading Companies, 2012
Table 4.4 US Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.5 Price Controls in Europe, 2013
Table 4.6 EU5 Countries: Pharma W&D Revenue Forecasts, 2012-2023
Table 4.7 German Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.8 French Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.9 Italian Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.10 Spanish Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.11 UK Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.12 Proportion of the Population Aged 65+ in US, Europe, Japan, China and India, 2025 and 2050
Table 4.13 Japanese Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.14 Chinese Pharmaceutical W&D Market: Shares of the Leading Companies, 2012
Table 4.15 Chinese Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.16 Brazilian Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.17 Indian Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.18 Russian Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 5.1 Leading Companies in the Pharmaceutical W&D Market: Revenues and Market Shares, 2012
Table 5.2 Leading W&D Companies: Revenue Forecasts, 2012-2023
Table 5.3 McKesson: Key Facts
Table 5.4 McKesson: Revenue and Profit Generation by Business Segment, 2012
Table 5.5 Pharmaceutical Distribution of Revenue: Geographical Breakdown of Revenue, 2012
Table 5.6 McKesson: Revenue and Market Share Forecast, 2012-2023
Table 5.7 Cardinal Health: Key Facts
Table 5.8 Cardinal Health: Breakdown of Revenue and Operating Earnings by Business Segment, 2012
Table 5.9 Cardinal Health: Revenue and Market Share Forecast, 2012-2023
Table 5.10 AmerisourceBergen: Key Facts
Table 5.11 AmerisourceBergen: Breakdown of Revenue by Business Segment, 2011 and 2012
Table 5.12 AmerisourceBergen: Revenue and Market Share Forecast, 2012-2023
Table 5.13 Alliance Boots: Key Facts
Table 5.14 Alliance Boots: Breakdown of Revenue and Profit by Business Segment, 2012
Table 5.15 Alliance Boots: Pharmaceutical W&D Breakdown by Country, 2012
Table 5.16 Alliance Boots: Revenue and Market Share Forecast, 2012-2023
Table 5.17 Medipal: Key Facts
Table 5.18 Medipal: Revenue and Operating Income by Business Segment, 2012
Table 5.19 Medipal: Revenue and Market Share Forecast, 2012-2023
Table 5.20 Celesio Pharmaceutical Wholesale: Operating Countries and Subsidiaries, 2012
Table 5.21 Celesio: Key Facts
Table 5.22 Celesio: Breakdown of Revenue and Gross Profit by Business Segment, 2012
Table 5.23 Celesio's Pharmacy Solutions: Breakdown of Revenue by Country, 2012
Table 5.24 Celesio: Revenue and Market Share Forecast, 2012-2023
Table 5.25 Alfresa Holdings: Key Facts
Table 5.26 Alfresa Holdings: List of Subsidiary Companies
Table 5.27 Alfresa Holdings: Revenue and Gross Profit by Business Segment, 2012
Table 5.28 Alfresa Holdings: Revenue and Market Share Forecast, 2012-2023
Table 5.29 The PHOENIX Group: Subsidiary Companies, 2012
Table 5.30 The PHOENIX Group: Key Facts
Table 5.31 The PHOENIX Group: Revenue and Market Share Forecast, 2012-2023
Table 5.32 Sinopharm: Key Facts
Table 5.33 Sinopharm: Revenue and Operating Profit by Business Segment, 2012
Table 5.34 Sinopharm: Revenue and Market Share Forecast, 2012-2023
Table 5.35 Suzuken: Key Facts
Table 5.36 Suzuken: Breakdown of Revenue and Operating Income by Business Segment, 2012
Table 5.37 Suzuken: Revenue and Market Share Forecast, 2012-2023
Table 5.38 Shanghai Pharma: Key Facts
Table 5.39 Shanghai Pharma: Breakdown of Operating Income by Business Segment, 2012
Table 5.40 Shanghai Pharma: Revenue and Market Share Forecast, 2012-2023
Table 6.1 The Pharmaceutical W&D Market: Strengths and Weaknesses, 2013
Table 6.2 The Pharmaceutical W&D Market: Opportunities and Threats, 2013-2023
Table 6.3 Strengths and Weaknesses of the DTP Distribution Model, 2013
Table 6.4 ITR Ratings and Corresponding Reimbursement Rates, 2013
Table 6.5 Social, Technological, Economic and Political Factors Influencing the Pharmaceutical W&D Market (STEP Analysis), 2012-2023
Table 2.1 Use of the DTP Model in the UK, 2013
Table 3.1 Pharmaceutical Wholesale and Distribution: World Market Forecast, 2012-2023
Table 3.2 Pharmaceutical W&D: Branded, Generic Drugs and Others, Revenue Forecasts, 2012-2023
Table 3.3 W&D of Branded Drugs: Revenue Forecast, 2012-2023
Table 3.4 W&D of Generic Drugs: Revenue Forecast, 2012-2023
Table 4.1 The Leading National Markets: Revenues and Market Shares, 2012
Table 4.2 The Leading National Markets: Revenue Forecasts, 2012-2023
Table 4.3 Breakdown of the US Market: The 3 Leading Companies, 2012
Table 4.4 US Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.5 Price Controls in Europe, 2013
Table 4.6 EU5 Countries: Pharma W&D Revenue Forecasts, 2012-2023
Table 4.7 German Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.8 French Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.9 Italian Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.10 Spanish Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.11 UK Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.12 Proportion of the Population Aged 65+ in US, Europe, Japan, China and India, 2025 and 2050
Table 4.13 Japanese Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.14 Chinese Pharmaceutical W&D Market: Shares of the Leading Companies, 2012
Table 4.15 Chinese Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.16 Brazilian Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.17 Indian Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 4.18 Russian Pharmaceutical W&D Market: Revenue and Market Share, 2012-2023
Table 5.1 Leading Companies in the Pharmaceutical W&D Market: Revenues and Market Shares, 2012
Table 5.2 Leading W&D Companies: Revenue Forecasts, 2012-2023
Table 5.3 McKesson: Key Facts
Table 5.4 McKesson: Revenue and Profit Generation by Business Segment, 2012
Table 5.5 Pharmaceutical Distribution of Revenue: Geographical Breakdown of Revenue, 2012
Table 5.6 McKesson: Revenue and Market Share Forecast, 2012-2023
Table 5.7 Cardinal Health: Key Facts
Table 5.8 Cardinal Health: Breakdown of Revenue and Operating Earnings by Business Segment, 2012
Table 5.9 Cardinal Health: Revenue and Market Share Forecast, 2012-2023
Table 5.10 AmerisourceBergen: Key Facts
Table 5.11 AmerisourceBergen: Breakdown of Revenue by Business Segment, 2011 and 2012
Table 5.12 AmerisourceBergen: Revenue and Market Share Forecast, 2012-2023
Table 5.13 Alliance Boots: Key Facts
Table 5.14 Alliance Boots: Breakdown of Revenue and Profit by Business Segment, 2012
Table 5.15 Alliance Boots: Pharmaceutical W&D Breakdown by Country, 2012
Table 5.16 Alliance Boots: Revenue and Market Share Forecast, 2012-2023
Table 5.17 Medipal: Key Facts
Table 5.18 Medipal: Revenue and Operating Income by Business Segment, 2012
Table 5.19 Medipal: Revenue and Market Share Forecast, 2012-2023
Table 5.20 Celesio Pharmaceutical Wholesale: Operating Countries and Subsidiaries, 2012
Table 5.21 Celesio: Key Facts
Table 5.22 Celesio: Breakdown of Revenue and Gross Profit by Business Segment, 2012
Table 5.23 Celesio's Pharmacy Solutions: Breakdown of Revenue by Country, 2012
Table 5.24 Celesio: Revenue and Market Share Forecast, 2012-2023
Table 5.25 Alfresa Holdings: Key Facts
Table 5.26 Alfresa Holdings: List of Subsidiary Companies
Table 5.27 Alfresa Holdings: Revenue and Gross Profit by Business Segment, 2012
Table 5.28 Alfresa Holdings: Revenue and Market Share Forecast, 2012-2023
Table 5.29 The PHOENIX Group: Subsidiary Companies, 2012
Table 5.30 The PHOENIX Group: Key Facts
Table 5.31 The PHOENIX Group: Revenue and Market Share Forecast, 2012-2023
Table 5.32 Sinopharm: Key Facts
Table 5.33 Sinopharm: Revenue and Operating Profit by Business Segment, 2012
Table 5.34 Sinopharm: Revenue and Market Share Forecast, 2012-2023
Table 5.35 Suzuken: Key Facts
Table 5.36 Suzuken: Breakdown of Revenue and Operating Income by Business Segment, 2012
Table 5.37 Suzuken: Revenue and Market Share Forecast, 2012-2023
Table 5.38 Shanghai Pharma: Key Facts
Table 5.39 Shanghai Pharma: Breakdown of Operating Income by Business Segment, 2012
Table 5.40 Shanghai Pharma: Revenue and Market Share Forecast, 2012-2023
Table 6.1 The Pharmaceutical W&D Market: Strengths and Weaknesses, 2013
Table 6.2 The Pharmaceutical W&D Market: Opportunities and Threats, 2013-2023
Table 6.3 Strengths and Weaknesses of the DTP Distribution Model, 2013
Table 6.4 ITR Ratings and Corresponding Reimbursement Rates, 2013
Table 6.5 Social, Technological, Economic and Political Factors Influencing the Pharmaceutical W&D Market (STEP Analysis), 2012-2023
Other pharmaceutical manufacturers have made several attempts to reduce parallel trade in the EU. Reportedly, Sandoz has reportedly stated “export prohibited” on invoices. Many manufacturers are also resorting to direct-to-pharmacy (DTP) distribution in other European countries in order to control the supply of drugs; quotas systems are introduced in order to ensure that wholesalers supplies can meet domestic demand, but a surplus is avoided. The European Court of Justice ruled that this practice is legal, but that quotas have to be introduced unilaterally. This means that pharmaceutical manufacturers cannot negotiate directly with pharmacies to agree quotas; specialist independent audit teams are required to fairly regulate quotas.
In 2008, the Spanish government introduced new margins that wholesalers could charge. Under these rules, for drugs valued at less than or equal to €91.63 wholesalers are able to apply a margin of 7.6%. For drugs worth over €91.63 a fixed margin of €7.54 can be added. In 2010, drug price cuts were announced by the government, cutting the price of branded products by 7.5% and generics by 25%. In 2012, the wholesale and distribution of pharmaceutical products in Spain generated revenue of $16.91bn, accounting for 2.27% of the global market.
Market Forecast, 2013-2023
The wholesaler cooperatives in Spain are non-profit making organisations; their apparent purpose is to serve the pharmacies. This allows them to be competitive in pricing, forcing commercial wholesalers to cut their margins to compete. This is likely to restrain market growth during the forecast period. However, the control these cooperatives hold over the distribution market means that it will be difficult for manufacturers to introduce a DTP system; the pharmacies like dealing with the wholesalers. It is likely that more restricted wholesale will be introduced, as manufacturers seek to reduce the risk of parallel trade. This will benefit the largest wholesalers and should help keep growth in the market steady, visiongain believes.
The Spanish wholesale market differs from that in France, Germany and the UK in that there are many more large wholesalers competing. However, as more restricted wholesale is introduced, there will be cooperative mergers, similar to that of Cofares and Hefame, leaving just a few to dominate the market by the end of the forecast period, visiongain predicts. Between 2013 and 2018, the Spanish pharmaceutical W&D market will expand at a CAGR of 3.9%. During the latter half of the forecast period, this rate of growth will slow; between 2018 and 2023 the market will expand at a CAGR of 3%. In 2023, the market will generate $24.66bn, accounting for 1.95% of the global market. This decrease in market share will result from rapid expansion in emerging markets such as India and China; these countries will capture market share from the developed economies.
The main market driver stems from the consolidation of cooperatives; this will place national wholesalers in a better position to negotiate pricing with manufacturers. The principal restraints on the market stem are cuts to drug prices which will result in lower revenue for wholesalers. Additionally, the high risk of parallel trade of medicines purchased in Spain is encouraging manufacturers to limit the number of wholesalers they use.
